We are thrilled to share the news of a $46MM award from ARPA-H, an agency within the U.S. Department of Health and Human Services (HHS), to support the development of our SONALA-001 sonodynamic therapy for the treatment of blood cancers.
See ARPA-H Post
Our work revolves around providing hope for patients.
How Sonodynamic Therapy Works for Treating Brain Tumors | Ivy Brain Tumor Center
Esther was the first diffuse intrinsic pontine glioma (DIPG) patient to be treated in a sonodynamic therapy trial in children. We are grateful to her family for sharing their experience.
We are committed to providing hope in the face of despair by developing a tumor-targeting drug (SONALA-001) together with an ultrasound device as sonodynamic therapy (SDT). This combination has the potential to be a safe and effective noninvasive treatment for cancer.
SonALAsense is the first company to advance SDT into clinical trials.
SDT is a Platform Technology
SonALAsense is pursuing a pipeline of additional indications utilizing SDT to treat multiple tumor types.
Our science targets cancer's own needs to cause it to destroy itself.
SDT metabolically targets cancer cells causing immediate and programmed cell death.
Clinical trials now recruiting, Contact Us to learn more about eligibility.